SIRT1 and Duchenne muscular dystrophy: Oral administration of SIRT2104, a selective SIRT1 activator, to DMD models of Drosophila melanogaster (DysE17) and mouse (mdx) demonstrated improved muscle morphology and function (Giovarelli et al., 2025).